Understanding Oligometastatic Disease in Prostate Cancer: Insights from PSMA PET Imaging

Key opinion leaders examine the role of advanced imaging agents, particularly PSMA PET and other radiotracers, in identifying and defining oligometastatic disease in patients with prostate cancer.

EP: 1.PSMA PET vs. Gallium-Based PET: Navigating NCCN Guidelines in Prostate Cancer Imaging

EP: 2.Insights into the Benefit of PSMA PET Imaging Alongside Other Conventional Imaging Modalities in Prostate Cancer Care

EP: 3.The Role of PSMA PET in Early Detection and Prostate Cancer Staging

Now Viewing

EP: 4.Understanding Oligometastatic Disease in Prostate Cancer: Insights from PSMA PET Imaging

EP: 5.Navigating Oligometastatic Disease: Understanding Lesion Numbers, Metastasis, and Disease Cutoffs in Clinical Practice

EP: 6.Evaluating Imaging Agents in Oligometastatic Prostate Cancer: A Comparative Analysis of Gallium-Based and Non-Gallium-Based Options

EP: 7.Optimal Timing and Frequency of Imagining Agents Used in the Detection and Characterization of Oligometastatic Prostate Cancer

EP: 8.Collaboration in Prostate Cancer Care: The Role of PSMA PET Imaging in Multidisciplinary Teams

EP: 9.Navigating Inter-readability Issues in Nuclear Medicine: Solutions for Limited Specialist Availability

EP: 10.Bridging the Gap: Key Considerations for Physicians Interpreting Gallium-Based PET Imaging

Video content above is prompted by the following:

• How do imaging agents, such as PSMA PET or other radiotracers, contribute to the detection and characterization of oligometastasis in prostate cancer patients?

Recent Videos